Form 4: Director Timothy Richards Increases Stake in ClearPoint

Director Timothy T. Richards acquired 442 shares of ClearPoint Neuro, Inc. common stock as compensation for board services.

Summary

• Director Timothy T. Richards received 442 shares of common stock on April 1, 2026.
• The shares were issued as payment for director fees under the company's Non-Employee Director Compensation Plan.
• The transaction was valued at $9.10 per share, based on the closing price on March 31, 2026.
• Following this transaction, the director's total beneficial ownership stands at 80,196 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Director demonstrates alignment with shareholders by accepting equity as compensation for board services.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

Not applicable as this is a routine disclosure of director compensation.

Industry Context

StockSavvy.ai notes that the issuance of equity to directors in lieu of cash is a standard corporate governance practice designed to preserve cash reserves and align board incentives with long-term shareholder value.

Comparison to Industry Standards

• The use of equity-based compensation for non-employee directors is consistent with standard practices for small-cap medical device companies.

Stakeholder Impact

• Minimal impact on shareholders as the transaction represents a standard compensation arrangement.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Insider Trading, Director Compensation, Form 4